Back to top
more

Accelerate Diagnostics (AXDX)

(Real Time Quote from BATS)

$0.85 USD

0.85
29,868

+0.08 (10.39%)

Updated Apr 19, 2024 12:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -43.55% and 20.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Accelerate Diagnostics (AXDX) Expands in In Vitro Diagnostics

by Zacks Equity Research

Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.

Bruker's (BRKR) New Collaboration to Use MALDI Biotyper System

by Zacks Equity Research

Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.

Accelerate Diagnostics (AXDX) Loses -25.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Accelerate Diagnostics (AXDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Accelerate Diagnostics (AXDX) Moves 12.7% Higher: Will This Strength Last?

by Zacks Equity Research

Accelerate Diagnostics (AXDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -57.33% and 26.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of 57.14% and 39.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Is Accelerate Diagnostics (AXDX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Accelerate Diagnostics (AXDX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.

Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Akero Therapeutics, Inc. (AKRO) and Accelerate Diagnostics (AXDX) have performed compared to their sector so far this year.

Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Accelerate Diagnostics (AXDX) and Cognition Therapeutics, Inc. (CGTX) have performed compared to their sector so far this year.

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 0% and 19.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement

by Zacks Equity Research

Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.

Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays

by Zacks Equity Research

Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.

Penumbra (PEN) Hits 52-Week High: What's Driving the Rise?

by Zacks Equity Research

Penumbra (PEN) outperforms the industry and the S&P 500, backed by investors' optimism about the recently released first-quarter 2023 results.

Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing

by Zacks Equity Research

Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.

Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -40% and 0.74%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics

by Zacks Equity Research

Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics are part of the Zacks Screen of the Week article.

Sanghamitra Saha headshot

Forget Bargain Hunting, Buy 5 Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nektar Therapeutics (NKTR).

Accelerate Diagnostics (AXDX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Accelerate Diagnostics (AXDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 12.50% and 0.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

PROCEPT BioRobotics Corporation (PRCT) delivered earnings and revenue surprises of -5.66% and 0.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Inari Medical, Inc. (NARI) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 35.29% and 0.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Nemaura Medical, Inc. (NMRD) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of 61.11% and 98.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ReWalk Robotics (RWLK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

ReWalk (RWLK) delivered earnings and revenue surprises of -28.57% and 3.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Veracyte (VCYT) delivered earnings and revenue surprises of 66.67% and 6.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?